Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

William Rote Biography and Net Worth

SVP of Travere Therapeutics

William Rote, Ph.D., has served as senior vice president of research and development for Travere Therapeutics since February 2017. He is responsible for discovery and translational research, regulatory affairs, quality assurance, biometrics, and technical operations including chemistry, manufacturing and controls (CMC).

Prior to joining Travere Therapeutics, Dr. Rote led clinical development at Ardea Biosciences, a wholly owned subsidiary of AstraZeneca. In this role, he was responsible for leading all aspects of clinical trial execution and analysis, including clinical operations, data management, and biostatistics. Prior to his role at Ardea, Dr. Rote held numerous positions of increasing responsibility at Amylin, including vice president and site head for R&D. He earned both his doctorate in pharmacology and bachelor’s in pre-medicine from Pennsylvania State University, and received postdoctoral training at the University of Michigan.

What is William E. Rote's net worth?: The estimated net worth of William E. Rote is at least $1.45 million as of September 9th, 2024. Dr. Rote owns 84,455 shares of Travere Therapeutics stock worth more than $1,450,937 as of December 22nd. This net worth estimate does not reflect any other investments that Dr. Rote may own. Additionally, Dr. Rote receives an annual salary of $748,020.00 as SVP at Travere Therapeutics. Learn More about William E. Rote's net worth.
How old is William E. Rote?: Dr. Rote is currently 61 years old. There are 5 older executives and no younger executives at Travere Therapeutics. Learn More on William E. Rote's age.
What is William E. Rote's salary?: As the SVP of Travere Therapeutics, Inc., Dr. Rote earns $748,020.00 per year. The highest earning executive at Travere Therapeutics is Dr. Eric M. Dube Ph.D., President, CEO & Director, who commands a salary of $1,400,000.00 per year. Learn More on William E. Rote's salary.
How do I contact William E. Rote?: The corporate mailing address for Dr. Rote and other Travere Therapeutics executives is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. Travere Therapeutics can also be reached via phone at (888) 969-7879 and via email at [email protected]. Learn More on William E. Rote's contact information.
Has William E. Rote been buying or selling shares of Travere Therapeutics?: William E. Rote has not been actively trading shares of Travere Therapeutics during the last ninety days. Most recently, William E. Rote sold 4,387 shares of the business's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.52, for a transaction totalling $50,538.24. Following the completion of the sale, the senior vice president now directly owns 84,455 shares of the company's stock, valued at $972,921.60. Learn More on William E. Rote's trading history.
Who are Travere Therapeutics' active insiders?: Travere Therapeutics' insider roster includes Steve Aselage (Director), Sandra Calvin (CAO), Laura Clague (CFO), Eric Dube (CEO), Peter Heerma (Insider), Elizabeth Reed (SVP), Noah Rosenberg (Insider), and William Rote (SVP). Learn More on Travere Therapeutics' active insiders.
Are insiders buying or selling shares of Travere Therapeutics?: During the last year, insiders at the sold shares 20 times. They sold a total of 172,896 shares worth more than $2,164,946.05. The most recent insider tranaction occured on November, 25th when CAO Sandra Calvin sold 12,090 shares worth more than $221,247.00. Insiders at Travere Therapeutics own 3.8% of the company. Learn More about insider trades at Travere Therapeutics.
Information on this page was last updated on 11/25/2024.

William E. Rote Insider Trading History at Travere Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/9/2024	Sell	4,387	$11.52	$50,538.24	84,455
2/1/2024	Sell	4,764	$8.71	$41,494.44	80,720
9/5/2023	Sell	1,815	$14.71	$26,698.65	61,173
1/24/2023	Sell	2,062	$21.50	$44,333.00	42,376
5/11/2022	Sell	1,563	$21.71	$33,932.73	43,672
1/24/2022	Sell	1,875	$24.98	$46,837.50
2/18/2021	Sell	2,500	$28.01	$70,025.00

William E. Rote Buying and Selling Activity at Travere Therapeutics

Travere Therapeutics Company Overview

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Today's Range

Now: $17.18

$17.13

$17.88

50 Day Range

MA: $18.17

$16.86

$19.85

2 Week Range

Now: $17.18

$5.12

$20.33

Volume

3,699,463 shs

Average Volume

1,396,496 shs

Market Capitalization

$1.34 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.69

First JFK… next Elon?

From Porter & Company | Ad

I share with you in this special investigative documentary.

William Rote Biography and Net Worth

What is William E. Rote's net worth?

How old is William E. Rote?

What is William E. Rote's salary?

How do I contact William E. Rote?

Has William E. Rote been buying or selling shares of Travere Therapeutics?

Who are Travere Therapeutics' active insiders?

Are insiders buying or selling shares of Travere Therapeutics?